# Orchid Pharma Limited (ORCHPHARMA)

> ORCHPHARMA closed at ₹836.45 on 30 Oct 2026, trailing P/E 467.0, market cap ₹5,009 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Orchid Pharma Limited (NSE: ORCHPHARMA) closed at ₹836.45 on 30 Oct 2026, +15.4% over one year, against a 52-week range of ₹480.00 – ₹1,143.50.

In the quarter ended 30 Jun 2026 (consolidated, filed 14 Aug 2026) it reported revenue of ₹304 cr and net profit of ₹3 cr, a 1.1% net margin; revenue grew 75.9% and profit fell 80.7% year on year.

On four consecutive filed quarters its trailing P/E is 467.0; since 28 May 2025 its own P/E has ranged from 32.0 to 900.2 (median 44.2), and today's reading is higher than 87% of those 352 trading days.

From the balance sheet dated 31 Mar 2026: return on equity 0.8%, ROCE 1.1%, debt-to-equity 0.19, Piotroski F-score 4 of 9.

Against 66 Healthcare peers on NSE: Net margin higher than 5% of 64 sector peers; PBT margin higher than 3% of 64 sector peers; ROE higher than 6% of 64 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹836.45 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -23.7% / +47.6% / +15.4% |
| 52-week low – high | ₹480.00 – ₹1,143.50 |
| Market capitalisation | ₹5,009 cr |
| Trailing P/E | 467.0 |
| Price / book | 3.20 |
| EV / EBITDA | 84.3 |
| Earnings yield | 0.2% |
| TTM EPS | ₹1.79 |
| TTM net profit | ₹11 cr |
| Quarter revenue | ₹304 cr |
| Quarter net profit | ₹3 cr |
| Net margin | 1.1% |
| Revenue growth (YoY) | +75.9% |
| Profit growth (YoY) | -80.7% |
| Return on equity | 0.8% |
| ROCE | 1.1% |
| Debt / equity | 0.19 |
| Current ratio | 1.89 |
| Free cash flow | ₹-264 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹6.8 cr |

## Questions

### What is the P/E ratio of Orchid Pharma Limited?

Orchid Pharma Limited's trailing P/E is 467.0, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 28 May 2025 its P/E has ranged 32.0–900.2.

### What were Orchid Pharma Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, Orchid Pharma Limited reported revenue of ₹304 cr and net profit of ₹3 cr (consolidated), filed with the exchange on 14 Aug 2026.

### What is Orchid Pharma Limited's ROE?

Return on equity is 0.8% based on the balance sheet dated 31 Mar 2026.

### Does Orchid Pharma Limited have debt?

Debt-to-equity is 0.19 on the balance sheet dated 31 Mar 2026.

### What is ORCHPHARMA's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, ORCHPHARMA traded between ₹480.00 and ₹1,143.50.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/ORCHPHARMA

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._